NCT00294788 is a Phase 1/Phase 2 clinical trial of Fluvax in Influenza, sponsored by Probiomics Ltd.

Who is sponsoring NCT00294788?

NCT00294788 is sponsored by Probiomics Ltd.

What drugs are being tested in NCT00294788?

Interventions in NCT00294788: Fluvax, PCC® (Lactobacillus fermentum VRI 003).

Is NCT00294788 still recruiting?

NCT00294788 is currently status unknown. Last updated 8 January 2007.

Last reviewed 2007-01-08 · How we verify

NCT00294788

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phase I/II Placebo-Controlled Study of Consumption of a Probiotic on HAI Titre Following Influenza Vaccination of Healthy Adult Subjects

Status unknown Phase 1/Phase 2 Last updated 8 January 2007

What this trial tests

Phase 1/Phase 2 trial testing Fluvax in Influenza in 300 participants. Status unknown.

Timeline

1 March 2006

1 January 2007

Quick facts

Lead sponsor	Probiomics Ltd
Phase	Phase 1/Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	300
Start date	1 March 2006
Estimated completion	1 January 2007
Sites	1 location across Australia

Drugs / interventions tested

Fluvax — full drug profile →
PCC® (Lactobacillus fermentum VRI 003) — full drug profile →

Conditions studied

Influenza — all drugs for Influenza →

Sponsor

Probiomics Ltd — full company profile →

Who can join

Adults 18 to 49, any sex, with Influenza. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The percentage enhancement of the immune response to Fluvax vaccine by PCC® compared to placebo as measured by hemagglutination inhibition (HAI) titre in the serum of subjects 4 weeks after vaccination

Sponsor's own description

This project aims to test the hypothesis that oral consumption of a specific strain of the probiotic bacterium Lactobacillus fermentum (trademarked PCC®) is able to significantly enhance the immune response to a vaccine for influenza.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Influenza

Currently open trials in the same condition.

NCT07215858 — BPL-1357 Against H1N1 Influenza Virus Challenge · Phase 2 · recruiting
NCT07496450 — A Study of mRNA-1018-H5 Pandemic Influenza Vaccine in Healthy Adults · Phase 3 · recruiting
NCT07302256 — A Clinical Trial of Influenza Virus Split Vaccine for Individuals Aged 60 Years and Above · Phase 1 · recruiting
NCT07431840 — Immune Defense Protein Impact On Respiratory Immune Outcomes · NA · recruiting
NCT07485855 — Influenza Vaccination Strategy for Patients With Hematologic Malignancy · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00294788 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Probiomics Ltd
Last refreshed: 8 January 2007

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00294788.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing